Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Inhibiting the PI3K signaling pathway: buparlisib as a new targeted option in breast carcinoma.

Literature DB >> 26510854

Inhibiting the PI3K signaling pathway: buparlisib as a new targeted option in breast carcinoma.

Abstract

Aberrations in the PI3K signaling pathway are frequently observed in patients with breast cancer. Because of that, PI3K inhibitors are attractive options for the treatment of breast cancer because PI3K is the most proximal component of the pathway other than receptor tyrosine kinases. Buparlisib is a potent and highly specific oral pan-class I PI3K inhibitor, which is currently under investigation in patients with breast cancer. In this article, we describe the PI3K signaling pathway, the prognostic value of PI3K pathway mutations, as well as the mechanism of action of buparlisib. Lastly, we discuss preliminary results of preclinical and clinical studies showing the efficacy and safety profile of this agent in breast cancer patients.

Entities: Chemical Disease Species

Keywords: Breast cancer; Buparlisib; PI3K inhibitor; PI3KCA; Targeted therapy

Mesh：

Substances：

Year: 2015 PMID： 26510854 DOI： 10.1007/s12094-015-1410-z

Source DB: PubMed Journal: Clin Transl Oncol ISSN： 1699-048X Impact factor: 3.405

51 in total

1. Mutational characterization of individual breast tumors: TP53 and PI3K pathway genes are frequently and distinctively mutated in different subtypes.

Authors: Sandrine Boyault; Youenn Drouet; Claudine Navarro; Thomas Bachelot; Christine Lasset; Isabelle Treilleux; Eric Tabone; Alain Puisieux; Qing Wang
Journal: Breast Cancer Res Treat Date: 2011-04-22 Impact factor: 4.872

2. Rheb binds tuberous sclerosis complex 2 (TSC2) and promotes S6 kinase activation in a rapamycin- and farnesylation-dependent manner.

Authors: Ariel F Castro; John F Rebhun; Geoffrey J Clark; Lawrence A Quilliam
Journal: J Biol Chem Date: 2003-07-03 Impact factor: 5.157

Review 3. Phosphatidylinositol 3-kinase and antiestrogen resistance in breast cancer.

Authors: Todd W Miller; Justin M Balko; Carlos L Arteaga
Journal: J Clin Oncol Date: 2011-10-17 Impact factor: 44.544

4. Mechanism of activation of protein kinase B by insulin and IGF-1.

Authors: D R Alessi; M Andjelkovic; B Caudwell; P Cron; N Morrice; P Cohen; B A Hemmings
Journal: EMBO J Date: 1996-12-02 Impact factor: 11.598

5. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.

Authors: Yoichi Nagata; Keng-Hsueh Lan; Xiaoyan Zhou; Ming Tan; Francisco J Esteva; Aysegul A Sahin; Kristine S Klos; Ping Li; Brett P Monia; Nina T Nguyen; Gabriel N Hortobagyi; Mien-Chie Hung; Dihua Yu
Journal: Cancer Cell Date: 2004-08 Impact factor: 31.743

6. PIK3CA mutation associates with improved outcome in breast cancer.

Authors: Kevin Kalinsky; Lindsay M Jacks; Adriana Heguy; Sujata Patil; Marija Drobnjak; Umeshkumar K Bhanot; Cyrus V Hedvat; Tiffany A Traina; David Solit; William Gerald; Mary Ellen Moynahan
Journal: Clin Cancer Res Date: 2009-08-11 Impact factor: 12.531

7. S6 kinase 1 regulates estrogen receptor alpha in control of breast cancer cell proliferation.

Authors: Rachel L Yamnik; Alla Digilova; Daphne C Davis; Z Nilly Brodt; Christopher J Murphy; Marina K Holz
Journal: J Biol Chem Date: 2008-12-27 Impact factor: 5.157

8. Mutations in the phosphatidylinositol-3-kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic Ras is a dominant predictor for resistance.

Authors: Nathan T Ihle; Robert Lemos; Peter Wipf; Adly Yacoub; Clint Mitchell; Doris Siwak; Gordon B Mills; Paul Dent; D Lynn Kirkpatrick; Garth Powis
Journal: Cancer Res Date: 2009-01-01 Impact factor: 12.701

9. Protein kinase B (c-Akt) in phosphatidylinositol-3-OH kinase signal transduction.

Authors: B M Burgering; P J Coffer
Journal: Nature Date: 1995-08-17 Impact factor: 49.962

10. Cloning and characterization of a G protein-activated human phosphoinositide-3 kinase.

Authors: B Stoyanov; S Volinia; T Hanck; I Rubio; M Loubtchenkov; D Malek; S Stoyanova; B Vanhaesebroeck; R Dhand; B Nürnberg
Journal: Science Date: 1995-08-04 Impact factor: 47.728

6 in total

Review 1. Solid Tumors and Kinase Inhibition: Management and Therapy Efficacy Evolution.

Authors: Flávia Melo Cunha de Pinho Pessoa; Caio Bezerra Machado; Emerson Lucena da Silva; Laudreísa da Costa Pantoja; Rodrigo Monteiro Ribeiro; Maria Elisabete Amaral de Moraes; Manoel Odorico de Moraes Filho; Raquel Carvalho Montenegro; André Salim Khayat; Caroline Aquino Moreira-Nunes
Journal: Int J Mol Sci Date: 2022-03-30 Impact factor: 5.923

2. Somatic alterations of TP53, ERBB2, PIK3CA and CCND1 are associated with chemosensitivity for breast cancers.

Authors: Libo Yang; Feng Ye; Longlong Bao; Xiaoyan Zhou; Zhe Wang; Peizhen Hu; Nengtai Ouyang; Xiaojuan Li; Yi Shi; Gang Chen; Peiyi Xia; Meiying Chui; Wencai Li; Ying Jia; Yueping Liu; Junjun Liu; Junyi Ye; Zhe Zhang; Hong Bu
Journal: Cancer Sci Date: 2019-03-19 Impact factor: 6.716